Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversing Ticagrelor in Subjects Aged 50 to 80 Years Old

NCT04122170 is registered in ClinicalTrials.gov with SFJ Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04122170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04122170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversing Ticagrelor in Subjects Aged 50 to 80 Years Old
Lead sponsor
SFJ Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 24, 2019
Completion date
September 1, 2021
Enrollment
207 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

healthy